key: cord-0922839-rxjt5655
authors: Chen, Muxin; Gao, Shitong; Ai, Lin; Chen, Jiaxu; Feng, Tiejian; Chen, Zhigao; Zhang, Xiaomin; Deng, Shaoyu; Lin, Zidan; Tang, Yijun; Zhang, Qian; He, Gengcheng; Xiong, Huawei; Zhou, Xiao-nong; Zhang, Renli; Huang, Dana
title: The First Reported Case of COVID-19 and Plasmodium ovale Malaria Coinfection — Guangdong Province, China, January 2021
date: 2021-05-21
journal: China CDC Wkly
DOI: 10.46234/ccdcw2021.101
sha: 81f9c60d274bd0bb84c42d523e04528e65e03bc2
doc_id: 922839
cord_uid: rxjt5655

nan

hours. The result of RT-PCR detection of COVID-19 virus swab tested negative on January 1, 2021. During hospitalization, the patient did not have cough, shortness of breath, or other respiratory symptoms including decreased oxygen levels or COVID-19 infection, and did not require any oxygen supply. On January 6, 2021, the blood smear test results were negative for P. ovale. According to his epidemiological history, clinical manifestations, and laboratory test results, this patient was preliminarily identified as an imported case of COVID-19 and P. o. wallikeri malaria coinfection in Uganda.

The patient was recently diagnosed with malaria on December 10, 2020 in Uganda, after which he left this area. During treatment on December 16, there was a possibility of reinfection, which suggested that COVID-19 might induce the current relapse of P. ovale. Similarly, a case of COVID-19 and P. vivax coinfection was reported by Kishore et al., which also highlighted the possibility of COVID-19 infection in inducing current malarial relapse (7) . Associated cytokine response with systematic illness has been postulated in P. vivax relapse (8) . The COVID-19 infection, with its cytokine response, was assumed to induce the P. ovale relapse of patient. More trials are needed to illustrate the mechanism of COVID-19 in inducing malaria relapse.

During the COVID-19 pandemic, consistent diagnosis of malaria and other infectious diseases should still be prioritized (7, (9) (10) (11) , especially in the areas with endemic infectious diseases such as those in Africa. In addition, invested funds related to malaria elimination were reduced or interrupted and might have lead to the interruption of malaria-related diagnostic tools and drug supply, which might have delayed targets and implementation of the malaria control strategies.

In conclusion, it is necessary to further study the risk factors, clinical outcomes, treatment challenges, and prognosis of cases on COVID-19 coinfection with other pathogens. Given the risk of these diseases, the China CDC Weekly following comprehensive prevention and control strategies were formulated: 1) 14 days of centralized isolation medical observation for entry personnel in medium and high-risk areas should be implemented, as well as screening for pathogens such as Plasmodium; 2) publicity and education on COVID-19 prevention and control of malaria and other diseases should be continued to reduce the burden of disease or death due to misdiagnosis and missed diagnoses; 3) it is necessary to build human health center communities that supplement existing prevention and control strategies for endemic infectious diseases including COVID-19, malaria, etc. Protecting the health and safety of the global community can only be accomplished with joint effort.

Funding 

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

How Shenzhen, China avoided widespread community transmission: a potential model for successful prevention and control of COVID-19

Mobility trends and effects on the COVID-19 epidemic -Hong Kong

Nested PCR analysis of Plasmodium parasites

Two nonrecombining sympatric forms of the human malaria parasite Plasmodium ovale occur globally

Plasmodium ovale curtisi and Plasmodium ovale wallikeri circulate simultaneously in African communities

COVID-19: possible cause of induction of relapse of Plasmodium vivax infection

Determinants of relapse periodicity in Plasmodium vivax malaria

Amambua-Ngwa A. Pausing the fight against malaria to combat the COVID-19 pandemic in Africa: is the future of malaria bleak?

COVID-19 and Plasmodium vivax malaria co-infection

SARS-CoV-2 and influenza virus co-infection